Swiss HealthTech startup developing a patented multi-tissue, multiplexed human in vitro platform with fluorescent markers to improve preclinical drug discovery and predict human-relevant drug effects across multiple tissue types.
Investment Rounds
Capital activity and funding progression
| Amount | Date | Round |
|---|---|---|
| €1.15 M | Jan, 2026 | seed |
Frequently Asked Questions
Where is FluoSphera located?
FluoSphera is located in Plan-les-Ouates, Switzerland.
What industries does FluoSphera operate in?
FluoSphera operates in the following industries: healthtech, biotechnology, drug-discovery, preclinical-testing, life-sciences.
How much total funding has FluoSphera raised?
FluoSphera has raised a total of $1,150,000.
Who are the investors in FluoSphera?
The investors in FluoSphera are: Soulmates Ventures, Swiss business angel, IndieBio New York.
Who are the founders of FluoSphera?
The founders of FluoSphera are: Dr. Clélia Bourgoint, Dr. Aurélien Roux, Aurélien Roux, Gregory Segala, Clélia Bourgoint.
What is the primary mission of FluoSphera?
FluoSphera aims to revolutionize drug discovery by replacing animal testing with more accurate human-relevant multi-tissue models. Their goal is to help drug developers predict how therapies will behave in the human body earlier and more reliably than traditional preclinical approaches.
How does the FluoSphera technology platform work without using chips?
Unlike traditional organ-on-a-chip systems, FluoSphera uses an encapsulation-based approach. Different human tissue types are physically isolated in micro-capsules but can communicate through soluble factors in a shared environment, mimicking natural inter-organ crosstalk without the need for external pumps or complex devices.
What is the significance of the color-coded capsules developed by FluoSphera?
The color-coded capsules allow researchers to tag and track individual tissue types within a single well. This enables the simultaneous analysis of multiple organs in one experiment, providing both global systemic insights and tissue-specific resolution in a high-throughput format.
How does FluoSphera help pharmaceutical companies reduce the cost of drug development?
By providing more reliable human systemic data early in the preclinical phase, FluoSphera helps developers identify promising molecules sooner and avoid costly late-stage failures. This can save companies hundreds of millions of dollars per molecule by reducing development risks and clinical trial attrition.
What specific role does FluoSphera play in the testing of Antibody-Drug Conjugates (ADCs)?
FluoSphera provides predictive tools to assess the tissue selectivity, systemic efficacy, and potential side effects of ADCs. Their platform offers a comprehensive human systemic profile that helps optimize these complex therapies and increase their chances of success in clinical trials.
Can the FluoSphera platform be used for high-throughput screening?
Yes, the platform is designed to be automation-friendly and compatible with standard high-throughput screening formats. This allows for large-scale, statistically robust testing workflows while maintaining the physiological relevance of multi-tissue interactions.
How does FluoSphera assist in identifying a drug's mode of action?
Through its FluoXplore solution, the company identifies systemic biomarkers and tracks drug effects across multiple tissues. Tissues can be sorted after the assay for further omics analysis, providing a holistic view of the drug's mechanisms and physiological impact.